Annexon, Inc.

76 articles about Annexon, Inc.

• Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  9/8/2020

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced second quarter 2020 financial results and recent highlights.

• Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer

  7/30/2020

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appointment of Michael Overdorf as Chief Business Officer. “I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our

• Annexon Announces Closing of Initial Public Offering

  7/28/2020

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of its initial public offering of 14,750,000 shares of its common stock at a public offering price of $17.00 per share.

• Annexon Announces Pricing of Initial Public Offering - July 24, 2020

  7/24/2020

  Annexon, Inc. announced the pricing of its initial public offering of 14,750,000 shares of its common stock at a public offering price of $17.00 per share.

• 

  Annexon Raises $100 Million to Advance Therapies for Neurodegenerative, Autoimmune Disorders

  7/2/2020

  Annexon, based in South San Francisco, closed on a $100 million Series C financing led by Redmile Group.

• Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics

  7/1/2020

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of a $100 million financing led by new investor Redmile Group.

•  Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

  10/9/2019

  Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks

• Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome

  9/30/2019

  Annexon Biosciences announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX005.

• Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome

  9/23/2019

  Annexon plans to advance the clinical development of ANX005 for the treatment of GBS

• 

  BioSpace Movers and Shakers, July 12

  7/12/2019

  Biotech and pharma companies strengthen their leadership teams with new appointments.

• Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders

  7/9/2019

  Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer

• 

  Companies Note Collaborations, Financing and Clinical Trial Success

  12/26/2018

  With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.

• Annexon Biosciences Closes $75 Million Financing

  12/19/2018

  Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.

• Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

  6/12/2018

  BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.

• Annexon Appoints Bill Young As Chairman And Adds Tom Wiggans To Board Of Directors

  3/9/2017

• Bay Area Startup Annexon Banks $44 Million Series B

  6/23/2016